TCL Archive FDA Says Bristol’s UFT “Not Approvable” For Colorectal Cancer, Contrary To ODAC. March 30, 2001
TCL Archive Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study December 26, 2014